An Exploratory Open-Label Biomarker Study of LY2127399 in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Synovial Biopsies
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2013
At a glance
- Drugs Tabalumab (Primary)
- Indications Rheumatoid arthritis
- Focus Biomarker; Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 07 Mar 2013 Planned End Date changed from 1 May 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.
- 21 Feb 2013 Planned end date changed from 1 Mar 2016 to 1 May 2013 as reported by ClinicalTrials.gov.